Search Result

Results for "

pulmonary hypertension

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (7) Aldehyde Dehydrogenase (ALDH) (1) AMPK (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (2) Apelin Receptor (APJ) (2) Apoptosis (7) Autophagy (3) Bacterial (3) c-Fms (1) c-Kit (1) Dopamine Receptor (2) Drug Metabolite (1) E1/E2/E3 Enzyme (2) Elastase (1) Endogenous Metabolite (2) Endothelin Receptor (9) ERK (1) Estrogen Receptor/ERR (3) Glutathione S-transferase (1) Guanylate Cyclase (3) HSP (1) Integrin (1) Isotope-Labeled Compounds (2) Leukotriene Receptor (2) LPL Receptor (2) Macrophage migration inhibitory factor (MIF) (1) Mitophagy (2) NADPH Oxidase (2) Neprilysin (2) P-glycoprotein (2) P2Y Receptor (1) PDGFR (2) Phosphodiesterase (PDE) (14) PPAR (2) Prostaglandin Receptor (8) SARS-CoV (2) Sodium Channel (1) STAT (1) TGF-β Receptor (4) TRP Channel (1) Tryptophan Hydroxylase (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (61) Endocrinology (5) Infection (4) Inflammation/Immunology (15) Metabolic Disease (6) Neurological Disease (4)

By Targets:

5-HT Receptor (7)

Aldehyde Dehydrogenase (ALDH) (1)

AMPK (1)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (2)

Apelin Receptor (APJ) (2)

Apoptosis (7)

Autophagy (3)

Bacterial (3)

c-Fms (1)

c-Kit (1)

Dopamine Receptor (2)

Drug Metabolite (1)

E1/E2/E3 Enzyme (2)

Elastase (1)

Endogenous Metabolite (2)

Endothelin Receptor (9)

ERK (1)

Estrogen Receptor/ERR (3)

Glutathione S-transferase (1)

Guanylate Cyclase (3)

HSP (1)

Integrin (1)

Isotope-Labeled Compounds (2)

Leukotriene Receptor (2)

LPL Receptor (2)

Macrophage migration inhibitory factor (MIF) (1)

Mitophagy (2)

NADPH Oxidase (2)

Neprilysin (2)

P-glycoprotein (2)

P2Y Receptor (1)

PDGFR (2)

Phosphodiesterase (PDE) (14)

PPAR (2)

Prostaglandin Receptor (8)

SARS-CoV (2)

Sodium Channel (1)

STAT (1)

TGF-β Receptor (4)

TRP Channel (1)

Tryptophan Hydroxylase (1)

By Research Areas:

Cancer (11)

Cardiovascular Disease (61)

Endocrinology (5)

Infection (4)

Inflammation/Immunology (15)

Metabolic Disease (6)

Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14184

Macitentan 10+ Cited Publications ACT-064992	Endothelin Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-14184S

Macitentan-d4 ACT-064992-d₄	Isotope-Labeled Compounds Endothelin Receptor Apoptosis	Cardiovascular Disease
Macitentan-d₄ is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].

HY-109190

Seralutinib 1 Publications Verification GB002; PK10571	PDGFR c-Fms c-Kit	Cardiovascular Disease
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC₅₀s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .

HY-105686

FR-229934	Phosphodiesterase (PDE)	Cardiovascular Disease
FR-229934 is a PDE V inhibitor extracted from patent WO2019130052A1. FR-229934 can be used for the research of pulmonary arterial hypertension and erectile dysfunction .

HY-154970A

BMPR2-IN-1 TFA	TGF-β Receptor	Cancer
BMPR2-IN-1 (Compound 8a) is a BMPR2 inhibitor with an IC₅₀ of 506 nM and a K_D of 83.5 nM. BMPR2-IN-1 can be used for research of pulmonary arterial hypertension, Alzheimer’s disease and cancer .

HY-148670

Pulmonary arterial hypertension agent-1	Others	Cardiovascular Disease
Pulmonary arterial hypertension agent-1 (example 15) is a pulmonary arterial hypertension agent . Pulmonary arterial hypertension agent-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P3227

Cyclo(Ala-Arg-Gly-Asp-Mamb) XJ735	Integrin	Inflammation/Immunology
Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension Research .

HY-170419

APJ receptor agonist 10	Apelin Receptor (APJ)	Cardiovascular Disease
APJ receptor agonist 10 (Compound I choline salt) modulates the activity of APJ receptor and can be used in research about pulmonary arterial hypertension. APJ receptor agonist 10 exhibits good bioavailability other than its free base form .

HY-14184R

Macitentan (Standard)	Endothelin Receptor Apoptosis	Cardiovascular Disease Endocrinology Cancer
Macitentan (Standard) is the analytical standard of Macitentan. This product is intended for research and analytical applications. Macitentan (ACT-064992) is an orally active, non-peptide dual ETA and ETB (endothelin receptor) antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) .

HY-154970

BMPR2-IN-1	TGF-β Receptor	Cancer
BMPR2-IN-1 (Compound 8a) is a BMPR2 inhibitor with an IC₅₀ of 506 nM and a K_D of 83.5 nM. BMPR2-IN-1 can be used for research of pulmonary arterial hypertension, Alzheimer’s disease and cancer .

HY-162888

WQ-C-401	PDGFR ERK	Cardiovascular Disease
WQ-C-401 is an orally active platelet-derived growth factor receptor (PDGFR) inhibitor. WQ-C-401 inhibits cell proliferation by blocking PDGFR autophosphorylation in a concentration-dependent manner, with EC₅₀ values of 3.5 nM for PDGFRα Y849 and 5.8 nM for PDGFRβ Y1021. Additionally, WQ-C-401 can inhibit PASMCs proliferation and migration by blocking PDGF-BB-induced ERK1/2 phosphorylation, reducing collagen I synthesis, and increasing α-SMA expression, thereby preventing pulmonary vascular remodeling. WQ-C-401 holds promise for research in the field of pulmonary arterial hypertension .

HY-153248

PBR28	Others	Others
PBR28 is an TSPO modulator, which can be used for prevention research of Pulmonary Arterial Hypertension (PAH). PBR28 can be used to trace 18 KDa transporter (TSPO) by adding radioactive labeling, which plays an important role in brain positron emission tomography (PET) imaging studies .

HY-150793

SY-LB-57	TGF-β Receptor	Cardiovascular Disease Neurological Disease
SY-LB-57 is a highly potent bone morphogenetic protein (BMP) receptor signaling agonist. SY-LB-57 can be used in studies of diseases such as fractures and pulmonary arterial hypertension .

HY-167891

GPD-1116	Phosphodiesterase (PDE) Apoptosis	Inflammation/Immunology
GPD-1116 is an orally active Phosphodiesterase (PDE) 4 and PDE1 inhibitor. GPD-1116 can reduce smoke-induced apoptosis of lung cells. GPD-1116 is effective in several disease models in animals, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma and pulmonary hypertension .

HY-129851

NTP42	Prostaglandin Receptor	Cardiovascular Disease
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC₅₀ of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca ²⁺] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .

HY-145413

BRD2889	Glutathione S-transferase	Cancer
BRD2889 is an analog of the alkaloid piperlongumine. BRD2889 is a robust modulator of the GSTP1-ISCU axis in pulmonary hypertension (PH) . BRD2889 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103459

CI-1020 PD156707	Endothelin Receptor	Cardiovascular Disease
CI-1020 (PD156707) is an orally active and selective antagonist targeting endothelin (ET_A) with an IC₅₀ value of 0.3 nM. CI-1020 blocks intimal hyperplasia in human saphenous veins completely in organ culture. CI 1020 inhibits hypoxic pulmonary hypertension and blocks ET-1-induced pressor responses following oral administration .

HY-149316

Smurf1-IN-1	E1/E2/E3 Enzyme	Cardiovascular Disease
Smurf1-IN-1 is an orally active and selective inhibitor of specific E3 ubiquitin protein ligase 1 (SMURF1) with an IC₅₀ of 92 nM. Smurf1-IN-1 has significant efficacy in rats model of pulmonary hypertension .

HY-90009

Nortadalafil Demethyl Tadalafil	Phosphodiesterase (PDE)	Cardiovascular Disease
Nortadalafil (Demethyl Tadalafil), a tadalafil (HY-90009A) analogue detected in health foods, is a highly selective PDE5 inhibitor. Nortadalafil is used in the research of erectile dysfunction (ED). Nortadalafil can be formed by closing the diketopiperazine ring in high yield. Nortadalafil is promising for research of pulmonary arterial hypertension .

HY-13569A

Beraprost sodium TRK-100; ML 1129 sodium	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost sodium (TRK-100), a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium (TRK-100) is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost sodium (TRK-100) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13569AR

Beraprost (sodium) (Standard)	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost (sodium) (Standard) is the analytical standard of Beraprost (sodium). This product is intended for research and analytical applications. Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-170435

PDE5-IN-13	Phosphodiesterase (PDE)	Cardiovascular Disease
PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC₅₀ of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active .

HY-90009R

Nortadalafil (Standard)	Phosphodiesterase (PDE)	Cardiovascular Disease
Nortadalafil (Standard) is the analytical standard of Nortadalafil. This product is intended for research and analytical applications. Nortadalafil , a new tadalafil (HY-90009A) analogue detected in health foods, is a PDE5 inhibitor. Nortadalafil is used in the research of erectile dysfunction (ED). Nortadalafil can be formed by closing the diketopiperazine ring in high yield. Nortadalafil is promising for research of pulmonary arterial hypertension [4] .

HY-155737

ET receptor antagonist 1	Estrogen Receptor/ERR	Cardiovascular Disease
ET receptor antagonist 1 (compound 16h) is an orally active ET receptor antagonist (IC₅₀=0.18 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 1 attenuates monocrotaline (HY-N0750) induced PAH in rat model .

HY-155739

ET receptor antagonist 3	Estrogen Receptor/ERR	Cardiovascular Disease
ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist (IC₅₀=0.26 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 3 attenuates monocrotaline (HY-N0750) induced PAH in rat model .

HY-155738

ET receptor antagonist 2	Estrogen Receptor/ERR	Cardiovascular Disease
ET receptor antagonist 2 (compound 16j) is an orally active ET receptor antagonist (IC₅₀=0.22 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 2 attenuates monocrotaline (HY-N0750) induced PAH in rat model .

HY-N0750

Monocrotaline Maximum Cited Publications 33 Publications Verification Crotaline	Others	Metabolic Disease Cancer
Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC₅₀s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. ^[2][6][8].

HY-168178

Hsp110-STAT3 interaction-IN-2	HSP STAT	Cardiovascular Disease
Hsp110-STAT3 interaction-IN-2 (compound 10b) is a Hsp110-STAT3 interaction disruptor. Hsp110-STAT3 interaction-IN-2 can be used in pulmonary arterial hypertension (PAH) related research .

HY-103080

CMF019	Apelin Receptor (APJ)	Cardiovascular Disease
CMF019 is an orally active, potent and small molecule agonist at Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ with pKi values of 8.58, 8.49 and 8.71 for human, rat, and mouse, respectively. CMF019 mimics the beneficial cardiovascular actions of apelin in rodents . Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin. CMF019 is promising for research of chronic diseases, such as, pulmonary arterial hypertension .

HY-A0126A

Epoprostenol sodium Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan	Endogenous Metabolite Apoptosis	Cardiovascular Disease
Epoprostenol sodium (Prostaglandin I2) sodium salt, the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH). Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-14779

Riociguat 15+ Cited Publications BAY 632521	Guanylate Cyclase	Cardiovascular Disease
Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.

HY-A0126AR

Epoprostenol sodium (Standard) Prostaglandin I2 sodium salt (Standard); Prostacyclin sodium salt (Standard); Flolan (Standard)	Endogenous Metabolite	Cardiovascular Disease
Epoprostenol (sodium) (Standard) is the analytical standard of Epoprostenol (sodium). This product is intended for research and analytical applications. Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH) . Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .

HY-168985

Mirivadelgat	Aldehyde Dehydrogenase (ALDH)	Cancer
Mirivadelgat is an activator of aldehyde dehydrogenase 2 activator. Mirivadelgat is promising for research of interstitial lung disease-pulmonary hypertension and cancers .

HY-14184A

Macitentan (n-butyl analogue)	Endothelin Receptor	Cardiovascular Disease Endocrinology
Macitentan n-butyl analogue is a n-butyl analogue of Macitentan. Macitentan is an orally active, non-peptide dual endothelin ETA and ETB receptor antagonist for the potential treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

HY-167906

Lunamarine	Bacterial Phosphodiesterase (PDE)	Metabolic Disease
Lunamarine is a inhibitor of PDE5 with BBB permeability. Lunamarine can be used in the reseach of Pulmonary Arterial Hypertension (PAH) and Erectile Dysfunction (ED) .

HY-P0012A

Aviptadil acetate 1 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P0012

Aviptadil 1 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-14779R

Riociguat (Standard)	Guanylate Cyclase	Cardiovascular Disease
Riociguat (Standard) is the analytical standard of Riociguat. This product is intended for research and analytical applications. Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.

HY-128593

TPN171	Phosphodiesterase (PDE)	Cardiovascular Disease
TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC₅₀ of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH) .

HY-115477

Brilaroxazine hydrochloride RP5063 hydrochloride	5-HT Receptor	Cardiovascular Disease
Brilaroxazine (RP5063) hydrochloride is a modulator of serotonin receptors, exhibiting potential therapeutic activity in the treatment of pulmonary arterial hypertension (PAH). Brilaroxazine hydrochloride has been shown to limit functional and structural changes associated with PAH, leading to significant improvements in pulmonary hemodynamics and right ventricular hypertrophy. Brilaroxazine hydrochloride also enhances oxygen saturation levels and alleviates elevated pulmonary arterial pressures when used as an adjunct to standard PAH therapies.

HY-117109

Amino Tadalafil	Phosphodiesterase (PDE)	Metabolic Disease
Amino Tadalafil is an analog of Tadalafil. Tadalafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with applications in several conditions, including erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract dysfunction.

HY-14779S

Riociguat-13C,d6 BAY 632521-¹³C,d₆	Isotope-Labeled Compounds	Cardiovascular Disease
Riociguat- ¹³C,d₆ is the ¹³C and deuterium labeled Riociguat (HY-14779). Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.

HY-90009S

Tadalafil-d3 IC-351-d₃	Phosphodiesterase (PDE)	Cardiovascular Disease
Tadalafil-d₃ is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.

HY-101124

Rodatristat ethyl KAR5585	Tryptophan Hydroxylase 5-HT Receptor	Cardiovascular Disease
Rodatristat ethyl (KAR5585) is a first-in-class oral tryptophan hydroxylase 1 (TPH1) Inhibitor with nanomolar in vitro potency. Rodatristat ethyl reduces the level of 5-HT and significantly reduces pulmonary arterial hypertension (PAH) .

HY-170387

MRS8209	5-HT Receptor	Cardiovascular Disease
MRS8209 is the antagonist for serotonin receptor with a K_i of 4.27 nM for 5-HT2BR. MRS8209 exhibits protective effect on pressure at airway opening (PAO), and can be used in research of pulmonary fibrosis .

HY-W700639

Tolafentrine	Phosphodiesterase (PDE)	Neurological Disease
Tolafentrine, a dual-selective phosphodiesterase 3/4 (PDE3/4) inhibitor, has been shown to have significant acute and chronic effects in a unilateral diacetamide-induced rat pulmonary hypertension model. Experiments show that long-term administration can significantly alleviate all unilateral bisacetamide-induced hemodynamic and gas exchange abnormalities, reduce right ventricular hypertrophy, and normalize pulmonary vascular remodeling changes .

HY-N0484

Liensinine 5+ Cited Publications	Autophagy Mitophagy Apoptosis	Cardiovascular Disease Cancer
Liensinine is an autophagy/mitophagy inhibitor. Liensinine, a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn, has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc .

HY-A0096A

(Z)-Iloprost (Z)-Ciloprost; (Z)-ZK 36374	Others	Cardiovascular Disease
(Z)-Iloprost ((Z)-Ciloprost; (Z)-ZK 36374) is a vasodilator that prevents heparin-induced platelet activation .

HY-117109R

Amino Tadalafil (Standard)	Phosphodiesterase (PDE)	Metabolic Disease
Amino Tadalafil (Standard) is the analytical standard of Amino Tadalafil. This product is intended for research and analytical applications. Amino Tadalafil is an analog of Tadalafil. Tadalafil is a potent inhibitor of phosphodiesterase 5 (PDE5) with applications in several conditions, including erectile dysfunction, pulmonary arterial hypertension, and lower urinary tract dysfunction.

HY-172094

AMPK-IN-6	AMPK Apoptosis Autophagy	Cardiovascular Disease
AMPK-IN-6 (compound 13a) is potent AMPK inhibitor with an IC₅₀ value of 0.093 µM. AMPK-IN-6 induces apoptosis and inhibits autophagy. AMPK-IN-6 shows antiproliferative activity. AMPK-IN-6 has the potential for the research of pulmonary arterial hypertension .

Cat. No.	Product Name

HY-L125

Anti-Pulmonary Fibrosis Compound Library

2,014 compounds

Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).

Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 2,014 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P0012A

Aviptadil acetate 1 Publications Verification Vasoactive Intestinal Peptide acetate salt (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-P0012

Aviptadil 1 Publications Verification Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)	SARS-CoV	Infection Inflammation/Immunology
Aviptadil is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al .

HY-12378

BQ-123 2 Publications Verification	Endothelin Receptor	Cardiovascular Disease
BQ-123 is a potent and selective endothelin A (ETA) receptor antagonist with an IC₅₀ of 7.3 nM and a K_i of 25 nM. BQ-123 inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .

HY-P1435

NoxA1ds	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds can be used in the study of hypertension, atherosclerosis and tumors .

HY-P3227

Cyclo(Ala-Arg-Gly-Asp-Mamb) XJ735	Integrin	Inflammation/Immunology
Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension Research .

HY-P1435A

NoxA1ds TFA	NADPH Oxidase	Cardiovascular Disease Cancer
NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC₅₀=20 nM). NoxA1ds TFA inhibits NOX1-derived O ^2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors .

Cat. No.	Product Name	Target	Research Area

HY-P99590

Sotatercept ACE-011	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

Cat. No.	Product Name	Category	Target	Chemical Structure